Autotaxin facilitates selective LPA receptor signaling

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Autotaxin (ATX) produces lysophosphatidic acid (LPA), a mediator involved in physiological and pathological processes like pulmonary fibrosis.
• ATX/LPA signaling is a potential drug target, but the clinical efficacy of different ATX inhibitor types is not well understood.

Purpose of the Study:

• To investigate how different ATX inhibitor classes modulate ATX/LPA signaling.
• To determine the role of the ATX 'tunnel' in ATX/LPA signaling and cellular responses.
• To compare the efficacy of tunnel-binding inhibitors versus active site-specific inhibitors in pulmonary fibrosis models.

Main Methods:

• Utilized primary lung fibroblasts and a murine model of radiation-induced pulmonary fibrosis.
• Assessed ATX/LPA signaling modulation by tunnel-binding inhibitors (e.g., ziritaxestat) and active site inhibitors.
• Investigated ATX catalytic activity-independent signaling pathways.

Main Results:

• The ATX 'tunnel' is critical for key ATX/LPA signaling aspects and cellular responses, independent of catalytic activity.
• Tunnel-binding inhibitors demonstrated greater efficacy in abrogating ATX/LPA signaling responses compared to active site inhibitors.
• A preference for P2Y G protein-coupled receptor activation was observed in ATX/LPA signaling.

Conclusions:

• ATX exhibits receptor-selective signaling mechanisms.
• Tunnel-targeting ATX inhibitors may offer greater clinical benefit in treating conditions like pulmonary fibrosis.